Global Oligonucleotide Synthesis Market Outlook, 2030

The Global Oligonucleotide Synthesis Market is experiencing substantial growth, propelled by advancements in genomics, molecular diagnostics, and biotechnology research. Oligonucleotides are short sequences of DNA or RNA that are chemically synthesized for various uses, such as drug development, genetic testing, polymerase chain reaction (PCR), and forensic analysis. The burgeoning demand for personalized medicine, rising investments in synthetic biology, and the growth of research in life sciences are driving the market’s growth. A key factor contributing to the growth of the oligonucleotide synthesis market is the increasing incidence of genetic disorders, infectious diseases, and chronic conditions such as cancer. Oligonucleotidebased therapies, including antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, are transforming disease treatment by targeting specific genes and proteins. These treatments show particular potential in addressing conditions such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and diverse forms of cancers, enhancing the demand for highquality synthetic oligonucleotides.

Garnering 9.7% from 2022 to 2028, the global oligonucleotide synthesis market is projected to reach worth of USD 10,989 million by 2028. The growth of molecular diagnostics is another significant contributor to market expansion. Methods like PCR, nextgeneration sequencing (NGS), and microarrays heavily depend on synthesized oligonucleotides for disease detection and genetic analysis. With the emergence of infectious diseases such as COVID19 and the rising adoption of precision medicine, the demand for oligonucleotidebased diagnostic assays has increased significantly. Moreover, advancements in CRISPR geneediting technology have elevated the use of oligonucleotides in genetic engineering, accelerating research in gene therapy and biotechnology. From a technological standpoint, innovations in solidphase chemical synthesis, enzymatic synthesis, and automation in oligonucleotide production have improved the efficiency, scalability, and costeffectiveness of synthesis processes. These developments have enabled pharmaceutical and biotech firms to produce oligonucleotides in bulk with high purity and precision, facilitating their widespread application in therapeutic and diagnostic fields. Pharmaceutical and biotechnology firms are essential to market growth by investing in oligonucleotidebased drug discovery and therapeutic applications. Major participants in the market, such as Thermo Fisher Scientific, Agilent Technologies, Integrated DNA Technologies, and BioSynthesis Inc. , are concentrating on strategic partnerships, mergers, and acquisitions to enhance their oligonucleotide synthesis capabilities.

The Global Oligonucleotide Synthesis Market is growing swiftly, with significant contributions from North America, Europe, AsiaPacific, and emerging areas in Latin America and the Middle East and Africa. These areas are at the forefront of research, development, and commercial uses of oligonucleotide synthesis, influenced by progress in genomics, molecular diagnostics, and therapeutic uses. North America, especially the United States, leads the oligonucleotide synthesis market. The U. S. hosts major biotech and pharmaceutical firms like Thermo Fisher Scientific, Agilent Technologies, and Integrated DNA Technologies, which are at the forefront of advancements in synthetic biology and genetic research. The existence of toptier research institutions, robust government funding, and rising investments in precision medicine are crucial factors driving market expansion. Canada also has an important role, emphasizing genomic research and drug development. Europe stands as another key player, with nations such as Germany, the United Kingdom, and France at the forefront in biotech innovations and pharmaceutical research. The European Medicines Agency (EMA) promotes oligonucleotidebased treatments, enhancing the market for synthetic DNA and RNA in drug discovery and diagnostics. Germany, in particular, boasts a strong biomanufacturing infrastructure, whereas the UK has achieved notable advancements in CRISPRbased gene editing and nextgeneration sequencing (NGS) technologies. The AsiaPacific region is undergoing the quickest growth, with China, Japan, and India becoming significant contributors. China has invested heavily in genetic research and synthetic biology, with organizations like BGI Genomics and WuXi AppTec expanding oligonucleotide production. India is becoming a global center for pharmaceutical manufacturing and molecular diagnostics, while Japan is concentrating on RNAbased therapeutics and gene therapy applications. Latin America and the Middle East and Africa are also experiencing steady growth, with nations like Brazil, Mexico, and South Africa boosting investments in biotech research and healthcare innovation. As global demand for genebased therapies and diagnostics increases, these areas are anticipated to take on a more significant role in the market.

The Global Oligonucleotide Synthesis Market is divided into oligonucleotide drugs, synthesized oligonucleotides, reagents, equipment, and services. Oligonucleotide drugs constitute a swiftly expanding sector owing to their rising application in genetic disorders, cancer treatment, and infectious disease therapies. Synthesized oligonucleotides find extensive use in PCR, gene editing (CRISPR), and DNA sequencing, rendering them vital for diagnostic and research purposes. Reagents like nucleotides, enzymes, and buffers are fundamental for the effective synthesis and alteration of oligonucleotides, guaranteeing high precision and stability. Equipment, comprising synthesizers and purification apparatus, is essential for largescale production of oligonucleotides. At the same time, services such as custom oligonucleotide synthesis and sequencing assist researchers and pharmaceutical companies in drug development, establishing it as a highly soughtafter market segment. With technological progress and escalating RandD, all these product categories are propelling market growth across various sectors. The use of oligonucleotide synthesis encompasses diagnostics, therapeutics, and research, with each being vital in healthcare and biotechnology. Diagnostics represents an important segment since oligonucleotide probes and primers are critical for PCR, microarrays, and nextgeneration sequencing (NGS) utilized in identifying infectious diseases, genetic disorders, and cancer biomarkers. In therapeutics, drugs based on oligonucleotides, including antisense oligonucleotides (ASOs), siRNA, and aptamers, are securing approvals for treating ailments like spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and uncommon genetic disorders. The progression of personalized medicine and gene therapy is further propelling this segment. Research applications involve utilizing oligonucleotides in gene expression research, synthetic biology, and drug discovery. Academic institutions and pharmaceutical firms depend on synthesized oligonucleotides for pushing forward biotechnology research, which leads to ongoing advancements in genomics and molecular biology.

Pharmaceutical and biotechnology companies are the primary consumers of oligonucleotides, employing them for drug development, gene therapy, and targeted RNAbased therapies. The increasing quantity of FDAapproved oligonucleotide medications, such as Spinraza and Exondys 51, has motivated pharmaceutical firms to invest in oligonucleotidebased therapies. With the rise of precision medicine, these organizations are concentrating on formulating personalized treatments for rare and chronic disorders, intensifying the demand for highquality synthetic oligonucleotides. Diagnostic laboratories depend on oligonucleotides for molecular diagnostics, disease screening, and forensic examinations. Oligonucleotide primers and probes are pivotal for PCRbased assessments, which have gained widespread attention in COVID19 testing, cancer diagnosis, and genetic screening. The growth of NGSbased diagnostics and companion diagnostics in oncology further enhances this sector, establishing oligonucleotides as vital in clinical environments. Academic research institutions are instrumental in the progress of synthetic biology, genetic engineering, and molecular biology. Universities and research facilities use oligonucleotides for gene expression research, CRISPRbased gene editing, and RNA interference (RNAi) studies. Government and private investments in biotechnology and genomic exploration have surged, allowing institutions to investigate new therapeutic targets, drug screening techniques, and synthetic DNA/RNA uses.



Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Global Oligonucleotide Synthesis Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By product:
• oligonucleotide drugs
• synthesized oligonucleotides
• reagents
• equipment
• services

By application:
• diagnostics
• therapeutics
• research

By end user:
• pharmaceutical & biotechnology companies
• diagnostic laboratories
• academic research institutes
The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.